BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32479084)

  • 1. Discovery of Novel Indole-Based Allosteric Highly Potent ATX Inhibitors with Great
    Lei H; Guo M; Li X; Jia F; Li C; Yang Y; Cao M; Jiang N; Ma E; Zhai X
    J Med Chem; 2020 Jul; 63(13):7326-7346. PubMed ID: 32479084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and PK-guided identification of indole-based non-acidic autotaxin (ATX) inhibitors exhibiting high in vivo anti-fibrosis efficacy in rodent model.
    Lei H; Cao Z; Wu H; Li T; Wang X; Chen Y; Ma E; Sun L; Zhai X
    Eur J Med Chem; 2022 Jan; 227():113951. PubMed ID: 34742015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.
    Nikolaou A; Ninou I; Kokotou MG; Kaffe E; Afantitis A; Aidinis V; Kokotos G
    J Med Chem; 2018 Apr; 61(8):3697-3711. PubMed ID: 29620892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
    Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
    FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based linker exploration: Discovery of 1-ethyl-1H-indole analogs as novel ATX inhibitors.
    Jia F; Lei H; Chen Y; Li T; Xing L; Cao Z; Zhai X
    Bioorg Med Chem; 2020 Nov; 28(22):115795. PubMed ID: 33032188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface.
    Fells JI; Lee SC; Fujiwara Y; Norman DD; Lim KG; Tsukahara R; Liu J; Patil R; Miller DD; Kirby RJ; Nelson S; Seibel W; Papoian R; Parrill AL; Baker DL; Bittman R; Tigyi G
    Mol Pharmacol; 2013 Sep; 84(3):415-24. PubMed ID: 23793291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.
    Ragle LE; Palanisamy DJ; Joe MJ; Stein RS; Norman DD; Tigyi G; Baker DL; Parrill AL
    Bioorg Med Chem; 2016 Oct; 24(19):4660-4674. PubMed ID: 27544588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure guided design of potent indole-based ATX inhibitors bearing hydrazone moiety with tumor suppression effects.
    Lei H; Li C; Yang Y; Jia F; Guo M; Zhu M; Jiang N; Zhai X
    Eur J Med Chem; 2020 Sep; 201():112456. PubMed ID: 32535330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of novel 2-pyrrolidinone and pyrrolidine derivatives and study of their inhibitory activity against autotaxin enzyme.
    Gerokonstantis DT; Nikolaou A; Magkrioti C; Afantitis A; Aidinis V; Kokotos G; Moutevelis-Minakakis P
    Bioorg Med Chem; 2020 Jan; 28(2):115216. PubMed ID: 31864778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of potent inhibitors of the lysophospholipase autotaxin.
    Shah P; Cheasty A; Foxton C; Raynham T; Farooq M; Gutierrez IF; Lejeune A; Pritchard M; Turnbull A; Pang L; Owen P; Boyd S; Stowell A; Jordan A; Hamilton NM; Hitchin JR; Stockley M; MacDonald E; Quesada MJ; Trivier E; Skeete J; Ovaa H; Moolenaar WH; Ryder H
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5403-5410. PubMed ID: 27780639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode.
    Miller LM; Keune WJ; Castagna D; Young LC; Duffy EL; Potjewyd F; Salgado-Polo F; Engel García P; Semaan D; Pritchard JM; Perrakis A; Macdonald SJ; Jamieson C; Watson AJ
    J Med Chem; 2017 Jan; 60(2):722-748. PubMed ID: 27982588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel imidazo[1,2-a]pyridine derivatives as potent ATX allosteric inhibitors: Design, synthesis and promising in vivo anti-fibrotic efficacy in mice lung model.
    Lei H; Li Z; Li T; Wu H; Yang J; Yang X; Yang Y; Jiang N; Zhai X
    Bioorg Chem; 2022 Mar; 120():105590. PubMed ID: 34998121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Potent
    Kawaguchi M; Okabe T; Okudaira S; Hama K; Kano K; Nishimasu H; Nakagawa H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
    J Med Chem; 2020 Mar; 63(6):3188-3204. PubMed ID: 32134652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.
    Stein AJ; Bain G; Prodanovich P; Santini AM; Darlington J; Stelzer NM; Sidhu RS; Schaub J; Goulet L; Lonergan D; Calderon I; Evans JF; Hutchinson JH
    Mol Pharmacol; 2015 Dec; 88(6):982-92. PubMed ID: 26371182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and therapeutic potential of autotaxin small molecule inhibitors: From bench to advanced clinical trials.
    Matralis AN; Afantitis A; Aidinis V
    Med Res Rev; 2019 May; 39(3):976-1013. PubMed ID: 30462853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of lysophosphatidic acid pathway modulators as therapies for fibrosis.
    Budd DC; Qian Y
    Future Med Chem; 2013 Oct; 5(16):1935-52. PubMed ID: 24175745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors.
    Joncour A; Desroy N; Housseman C; Bock X; Bienvenu N; Cherel L; Labeguere V; Peixoto C; Annoot D; Lepissier L; Heiermann J; Hengeveld WJ; Pilzak G; Monjardet A; Wakselman E; Roncoroni V; Le Tallec S; Galien R; David C; Vandervoort N; Christophe T; Conrath K; Jans M; Wohlkonig A; Soror S; Steyaert J; Touitou R; Fleury D; Vercheval L; Mollat P; Triballeau N; van der Aar E; Brys R; Heckmann B
    J Med Chem; 2017 Sep; 60(17):7371-7392. PubMed ID: 28731719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
    Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
    Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for specific inhibition of Autotaxin by a DNA aptamer.
    Kato K; Ikeda H; Miyakawa S; Futakawa S; Nonaka Y; Fujiwara M; Okudaira S; Kano K; Aoki J; Morita J; Ishitani R; Nishimasu H; Nakamura Y; Nureki O
    Nat Struct Mol Biol; 2016 May; 23(5):395-401. PubMed ID: 27043297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors.
    Magkrioti C; Kaffe E; Stylianaki EA; Sidahmet C; Melagraki G; Afantitis A; Matralis AN; Aidinis V
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.